Abstracts tagged "osteoarthritis and pain management"

Abstract Number: 2195 • 2019 ACR/ARP Annual Meeting
BMI Has Minimal Effect on Reduction of Symptoms in Patients with Osteoarthritis of the Knee Treated with Diclofenac 1% Gel
Joel A. Block¹, Bharat Patel ² and Sandy Yacoub Garas ³, ¹Rush University Medical Center, Chicago, IL, ²GlaxoSmithKline Consumer Healthcare, Weybridge, United Kingdom, ³GlaxoSmithKline Consumer Healthcare, Warren, NJ
Background/Purpose: Clinical trials demonstrate that diclofenac sodium gel 1% (DSG 1%), a topical NSAID, provides significantly better pain relief than vehicle placebo for patients with…
Abstract Number: 2197 • 2019 ACR/ARP Annual Meeting
Clinically Relevant Improvements in Knee Osteoarthritis Pain with Diclofenac Sodium Gel 1%
Marc C. Hochberg¹, Bharat Patel ², Sandy Yacoub Garas ³ and Roy Altman ⁴, ¹University of Maryland School of Medicine, Baltimore, MD, ²GlaxoSmithKline Consumer Healthcare, Weybridge, United Kingdom, ³GlaxoSmithKline Consumer Healthcare, Warren, NJ, ⁴University of California, Los Angeles
Background/Purpose: Topical agents are recommended for the initial treatment of patients with knee osteoarthritis (OA). Diclofenac sodium gel 1% (DSG 1%), a topical nonsteroidal anti-inflammatory…
Abstract Number: L20 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Subcutaneous Tanezumab for the Treatment of Osteoarthritis of the Hip or Knee
Thomas J. Schnitzer¹, Richard Easton², Shirley Pang³, Dennis Levinson⁴, Glenn Pixton⁵, Lars Viktrup⁶, Isabelle Davignon⁷, Mark T. Brown⁷, Kenneth M. Verburg⁷ and Christine R. West⁷, ¹Northwestern University, Chicago, IL, ²Michigan Orthopaedic & Spine Surgeons, Rochester Hills, MI, ³St. Jude Medical Center, Fullerton, CA, ⁴Chicago Clinical Research Institute, Chicago, IL, ⁵Pfizer, Inc., Morrisville, NC, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Pfizer, Inc., Groton, CT
Background/Purpose: Tanezumab is a humanized mAb that blocks nerve growth factor (NGF) and is in clinical development for chronic pain treatment. Tanezumab administered intravenously has…
Abstract Number: 440 • 2018 ACR/ARHP Annual Meeting
Assessing Inappropriate Pain Management in Adults with Hip or Knee Osteoarthritis Treated with Different Opioid Intensity Regimens: Results from a Retrospective Database Analysis
Nathaniel P. Katz^1,2, Kavita Gandhi³, Wenhui Wei⁴, Ahong Huang⁵ and Li Wang⁶, ¹President, Analgesic Solutions, Natick, MA, ²Tufts University School of Medicine, Boston, MA, ³Director, Global Health Economics and Outcomes Research, Teva Pharmaceutical Industries, Frazer, PA, ⁴Senior Director, Health Economics and Outcomes Research (HEOR), Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Project Manager, STATinMED Research, Dallas, TX, ⁶Senior Director, Analytic Research, STATinMED Research, Dallas, TX
Background/Purpose: Opioids are often prescribed for osteoarthritis (OA) pain management despite the need for balancing their risks and benefits. Since there are no standard criteria…
Abstract Number: 1354 • 2018 ACR/ARHP Annual Meeting
Correlates of Neuropathic Pain in Knee Osteoarthritis: The Modified Paindetect Questionnaire and the Osteoarthritis Initiative
Joshua Bernick¹, Wilma M. Hopman^2,3, Marc C. Hochberg⁴ and Jacqueline Hochman⁵, ¹Queen's University, Kingston, ON, Canada, ²Research Methodologist, Kingston General Health Research Institute, Queen's University, Kingston, ON, Canada, ³Adjunct Faculty, Department of Public Health Sciences, Faculty of Medicine, Queen's University, Kingston, ON, Canada, ⁴Head, Division of Rheumatology & Clinical Immunology; Vice Chair, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, ⁵Women's College Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Cumulative evidence suggests central sensitization contributes to a neuropathic-like phenotype in a subset of patients with knee osteoarthritis (OA). Using a variety of validated…
Abstract Number: 15L • 2017 ACR/ARHP Annual Meeting
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Titration-to-Effect Study of Orally Administered CR845 in Patients with Osteoarthritis of the Hip or Knee
Sukirti Bagal, Catherine Munera, Patricia Brady and Joseph Stauffer, Cara Therapeutics, Stamford, CT

Background/Purpose: CR845 is a selective kappa opioid receptor agonist with a peripheral mechanism of action. Here we report preliminary results from a Phase 2b study…
Abstract Number: 2224 • 2017 ACR/ARHP Annual Meeting
Analgesic Potential of NEO6860, a Modality Selective TRPV1 Antagonist, in Osteoarthritis Knee Pain: Results of a Randomized, Controlled, Proof-of-Concept Trial
Pierre Arsenault¹, Richard Leff², Nathaniel Katz³, Philippe Walker⁴ and Dan Chiche⁴, ¹Diex Recherche Sherbrooke, Sherbrooke, QC, Canada, ²Richard L Leff LLC, Chadds Ford, PA, ³Analgesic Solutions, Natick, MA, ⁴NEOMED Institute, Montreal, QC, Canada
Background/Purpose: Current treatments of osteoarthritis (OA) of the knee, such as NSAIDs, have significant limitations in both efficacy and safety. NEO6860 is a modality selective…
Abstract Number: 2235 • 2017 ACR/ARHP Annual Meeting
Factors Associated with Opioid Use in End-Stage Knee, Hip and Spine Osteoarthritis
J. Denise Power¹, Anthony V. Perruccio¹, Rajiv Gandhi¹, Christian Veillette¹, J. Roderick Davey¹, Stephen J. Lewis¹, Khalid Syed¹, Nizar Mahomed¹ and Y. Raja Rampersaud², ¹Arthritis Program, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Arthritis Program, Krembil Research Institute, University Health Network, Torotno, ON, Canada
Background/Purpose: The use of prescription opioids has been under increasing scrutiny due to concerns about the potential for misuse, dependency and increased adverse events. The…
Abstract Number: 311 • 2016 ACR/ARHP Annual Meeting
Comparative Effectiveness of Ayurveda and Conventional Care in Knee Osteoarthritis – a Randomized Controlled Trial
Christian Kessler^1,2, Kartar Dhiman³, Abhimanyu Kumar⁴, Thomas Ostermann⁵, Shivenarain Gupta^6,7, Antonio Morandi⁸, Martin Mittwede^7,9, Elmar Stapelfeldt², Michaela Spoo², Katja Icke¹, Andreas Michalsen^1,2 and Claudia Witt^1,10, ¹Institute for Social Medicine, Epidemiology and Health Economics, Charité University Medical Center, Berlin, Germany, ²Department for Complementary Medicine, Immanuel Hospital Berlin, Berlin, Germany, ³Central Council for Research in Ayurvedic Sciences (CCRAS), New Delhi, India, New Delhi, India, ⁴All India Institute of Ayurveda, New Delhi, India, ⁵Department of Psychology and Psychotherapy, University of Witten Herdeckey, Witten, Germany, ⁶Department of Kaya Cikitsa, J.S. Ayurveda College & P.D. Patel Ayurveda Hospital, Nadiad, India, ⁷European Academy of Ayurveda, Birstein, Germany, ⁸Ayurvedic Point, School of Ayurvedic Medicine, Milan, Italy, ⁹Department of Theology and Religious Sciences, University of Frankfurt, Frankfurt, Germany, ¹⁰Institute of Complementary and Integrative Medicine, University Hospital and University of Zurich, Zürich, Switzerland
Background/Purpose: Ayurveda is used to treat knee osteoarthritis (OA) despite limited evidence. We aimed to evaluate the effectiveness of complex multimodality Ayurvedic treatment in comparison…
Abstract Number: 1018 • 2016 ACR/ARHP Annual Meeting
Dietary Intake of Fiber and Risk of Knee Osteoarthritis
Zhaoli (Joy) Dai¹, Jingbo Niu¹, Yuqing Zhang², Paul Jacques³ and David T. Felson⁴, ¹Clinical epidemiology research and training unit, Boston University School of Medicine, Boston, MA, ²Clinical Epidemiology and Training Unit, Boston University School of Medicine, Boston, MA, ³Jean Mayer USDA Human Nutrition Research Center on Aging and Friedman School of Nutrition Science and Policy, Tufts University, Boston, Boston, MA, ⁴Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Dietary fiber reduced risks of metabolic diseases in part by reducing systemic inflammation and body weight. These factors are both likely to contribute to…
Abstract Number: 2186 • 2016 ACR/ARHP Annual Meeting
Analgesic Use and Subsequent Risk of Falls in Participants with or at Risk of Knee Osteoarthritis
Wei-Hsuan Lo-Ciganic¹, Lysbeth Floden², Erin L. Ashbeck³, Lili Zhou¹ and C. Kent Kwoh^3,4, ¹Department of Pharmacy, Practice and Science, University of Arizona, College of Pharmacy, Tucson, AZ, ²Department Pharmacy, Practice and Science, University of Arizona, College of Pharmacy, Tucson, AZ, ³The University of Arizona Arthritis Center, Tucson, AZ, ⁴Rheumatology, University of Arizona, College of Medicine, Tucson, AZ
Background/Purpose: Analgesics including opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), antidepressants, and nutraceuticals are commonly used for pain relief in osteoarthritis (OA). Although it has been reported…
Abstract Number: 3134 • 2016 ACR/ARHP Annual Meeting
Hydroxychloroquine Is Not Effective in Reducing Symptoms of Hand Osteoarthritis: Results from a Placebo-Controlled Randomised Trial
Sarah R. Kingsbury¹, Puvan Tharmanathan², Ada Keding³, Sarah Ronaldson³, Andrew Grainger⁴, Richard J. Wakefield⁵, Catherine Arundel³, Fraser Birrell⁶, Michael Doherty⁷, Tonia Vincent⁸, Fiona E Watt⁹, Krysia Dziedzic¹⁰, Terence W. O'Neill¹¹, Nigel K Arden¹², David L Scott¹³, John Dickson¹⁴, Toby Garrood¹⁵, Michael Green^16,17, Ajit Menon¹⁸, Tom Sheeran¹⁹, David Torgerson³ and Philip G. Conaghan⁴, ¹Section of Musculoskeletal Disease, Chapel Allerton Hospital, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, Leeds, United Kingdom, ²University of York, York, United Kingdom, ³Health Sciences, University of York, York, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵University of Leeds, Leeds, United Kingdom, ⁶Institute for Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁷Academic Rheumatology, University of Nottingham, Nottingham, Great Britain, ⁸University of Oxford, London, Great Britain, ⁹Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ¹⁰Institute for Primary Care and Health Sciences, Keele University, Staffordshire, United Kingdom, ¹¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Centre for Musculoskeletal Research, Manchester, United Kingdom, ¹²Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom, ¹³Department of Rheumatology, King's College London, London, United Kingdom, ¹⁴South Tees Hospitals NHS Foundation Trust, Middlesbrough, United Kingdom, ¹⁵Rheumatology, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom, ¹⁶York Teaching Hospital NHS Foundation Trust, York, United Kingdom, ¹⁷Harrogate and District NHS Foundation Trust, Harrogate, United Kingdom, ¹⁸Haywood Hospital, Stoke-On-Trent, United Kingdom, ¹⁹Cannock Chase Hospital, Cannock, United Kingdom
Background/Purpose: Synovitis is prevalent in OA and associated with pain. Hydroxychloroquine (HCQ) is used routinely for treating synovitis in inflammatory arthritis. The primary aim of…
Abstract Number: 1433 • 2015 ACR/ARHP Annual Meeting
Predicting Response to Osteoarthritis Treatment Based on Patient Reported Outcome Measures and Quantitative Sensory Testing
Kristine Phillips¹, David A. Williams², Arnold Gammaitoni³, J. Ryan Scott⁴, Steven E. Harte⁴, Susan L. Murphy⁵ and Daniel J. Clauw⁶, ¹Internal Medicine, University of Michigan, Ann Arbor, MI, ²Anesthseiology, University of Michigan, Ann Arbor, MI, ³Zogenix, Inc, San Diego, CA, ⁴Department of Anesthesiology, University of Michigan, Ann Arbor, MI, ⁵Phyiscal Medicine & Rehabilitation, University of Michigan, Ann Arbor, MI, ⁶Anesthesiology, University of Michigan, Ann Arbor, MI
Background/Purpose: Recent studies have suggested that a subset of individuals with arthritis have a component of sensitization to their pain. This subset of patients with…
Abstract Number: 2239 • 2014 ACR/ARHP Annual Meeting
Efficacy of Ketoprofen Lysine Salt in Reducing Inflammation and Pain in Primary Osteoarthritis of the Hand: Preliminary Results of a Retrospective and Prospective Clinical Trial
Maurizio Muratore¹, Laura Quarta¹, Antonella Grimaldi¹, Daniela Costanza¹, Luigi Lanata², Michela Bagnasco², Alessandra Monguzzi² and Eugenio Quarta¹, ¹Department of Rheumatology, Hospital Galateo, San Cesario di Lecce, Italy, ²Medical Department, Dompé SpA, Milan, Italy
Background/Purpose: Osteoarthritis (OA) is a common progressive joint disease and a leading cause of musculoskeletal pain and functional disability worldwide. Despite various interventional treatment approaches…
Abstract Number: 1451 • 2014 ACR/ARHP Annual Meeting
Use of Analgesics in Patients with Knee and/or Hip Osteoarthritis: Results from the Amsterdam Osteoarthritis Cohort
Joyce van Tunen¹, Marike van der Leeden^1,2, Martin van der Esch¹, Leo D. Roorda¹, Willem F. Lems^3,4 and Joost Dekker⁵, ¹Amsterdam Rehabilitation Research Center | Reade, Amsterdam, the Netherlands, Amsterdam, Netherlands, ²Rehabilitation Medicine/EMGO, VU University Medical Center, Amsterdam, Netherlands, ³Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, the Netherlands, Amsterdam, Netherlands, ⁴Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁵Rehabilitation Medicine, Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose Use of analgesics is recommended by international guidelines to reduce pain complaints related to knee and/or hip osteoarthritis. Underuse of analgesics might be substantial…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].